Joseph Schwartz
Stock Analyst
(2.91)
# 1,256
Out of 4,648 analysts
142
Total ratings
35.83%
Success rate
0.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $18.10 | +120.99% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $9.26 | +51.19% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.26 | +22.70% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.08 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.66 | +112.01% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $4.01 | +99.50% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.49 | +302.68% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.54 | +273.83% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.43 | -30.07% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $5.32 | +12.78% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $40.39 | +18.84% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $23.93 | -24.78% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $11.63 | +71.97% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $38.44 | -11.55% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $66.01 | +96.94% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $123.07 | +30.01% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $125.77 | +29.60% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $0.89 | +1,028.29% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $6.79 | +386.01% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $7.21 | +66.44% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $51.06 | +111.52% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $68.09 | -26.57% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $56.82 | -31.36% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.56 | +156.41% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $34.48 | -12.99% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $44.82 | +11.56% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $46.76 | -35.84% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $5.56 | +907.19% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $11.33 | +23.57% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $3.63 | +230.58% | 2 | Sep 26, 2017 |
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $18.10
Upside: +120.99%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $9.26
Upside: +51.19%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.26
Upside: +22.70%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.66
Upside: +112.01%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $4.01
Upside: +99.50%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.49
Upside: +302.68%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.54
Upside: +273.83%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.43
Upside: -30.07%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $5.32
Upside: +12.78%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $40.39
Upside: +18.84%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $23.93
Upside: -24.78%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.63
Upside: +71.97%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $38.44
Upside: -11.55%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $66.01
Upside: +96.94%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $123.07
Upside: +30.01%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $125.77
Upside: +29.60%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.89
Upside: +1,028.29%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $6.79
Upside: +386.01%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $7.21
Upside: +66.44%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $51.06
Upside: +111.52%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $68.09
Upside: -26.57%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $56.82
Upside: -31.36%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.56
Upside: +156.41%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $34.48
Upside: -12.99%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $44.82
Upside: +11.56%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $46.76
Upside: -35.84%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $5.56
Upside: +907.19%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $11.33
Upside: +23.57%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $3.63
Upside: +230.58%